OTCBB ALERTS

[buythebuy]

USRM SUNRISE, FL / ACCESSWIRE / June 8, 2016 / U.S. STEM CELL, Inc. (USRM) - The Chief Science Officer of U.S. Stem Cell Inc, Kristin Comella, and a team of researchers published a paper in the Journal of Translational Medicine. The team investigated the effects of the intra-myocardial implantation of stromal vascular fraction (SVF) in patients with chronic ischemic cardiomyopathy. A total of 28 patients underwent a local tumescent liposuction procedure to remove approximately 60 ml of fat tissue from the abdomen. The fat was separated to isolate the SVF and the cells were delivered into the scar region using the MyoCath® catheter delivery system in patients who had experienced a previous myocardial infarct. The subjects were then monitored for adverse events, ejection fraction via echocardiogram and 6-minute walk test (6MWT) over a period of 6 months. The average ejection fraction was 29% at baseline and significantly increased to 35% at both 3 and 6 months. Patients walked an average of 349 meters at baseline and demonstrated a statistically significant improvement at 3 and 6 months' post treatment of more than 80 meters. More importantly, the procedure demonstrated a strong safety profile with no severe adverse events or complications linked to the therapy.